ME03446B - Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera - Google Patents

Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera

Info

Publication number
ME03446B
ME03446B MEP-2019-215A MEP2019215A ME03446B ME 03446 B ME03446 B ME 03446B ME P2019215 A MEP2019215 A ME P2019215A ME 03446 B ME03446 B ME 03446B
Authority
ME
Montenegro
Prior art keywords
ser
val
leu
thr
lys
Prior art date
Application number
MEP-2019-215A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Nicolas Poirier
Caroline Mary
Original Assignee
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ose Immunotherapeutics filed Critical Ose Immunotherapeutics
Publication of ME03446B publication Critical patent/ME03446B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MEP-2019-215A 2016-02-29 2017-02-28 Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera ME03446B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301271P 2016-02-29 2016-02-29
PCT/IB2017/000293 WO2017149394A1 (en) 2016-02-29 2017-02-28 Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment
EP17716593.3A EP3423496B1 (en) 2016-02-29 2017-02-28 Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment

Publications (1)

Publication Number Publication Date
ME03446B true ME03446B (me) 2020-01-20

Family

ID=58530580

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-215A ME03446B (me) 2016-02-29 2017-02-28 Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera

Country Status (23)

Country Link
US (1) US11230602B2 (enExample)
EP (1) EP3423496B1 (enExample)
JP (1) JP7053479B2 (enExample)
KR (1) KR102819051B1 (enExample)
CN (1) CN109195987B (enExample)
AU (1) AU2017225495B2 (enExample)
BR (1) BR112018067479A2 (enExample)
CY (1) CY1122072T1 (enExample)
DK (1) DK3423496T3 (enExample)
ES (1) ES2737307T3 (enExample)
HR (1) HRP20191445T1 (enExample)
HU (1) HUE045183T2 (enExample)
IL (1) IL261330B2 (enExample)
LT (1) LT3423496T (enExample)
MA (1) MA43767B1 (enExample)
MD (1) MD3423496T2 (enExample)
ME (1) ME03446B (enExample)
PL (1) PL3423496T3 (enExample)
PT (1) PT3423496T (enExample)
RS (1) RS59223B1 (enExample)
SI (1) SI3423496T1 (enExample)
SM (1) SMT201900460T1 (enExample)
WO (1) WO2017149394A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2955196A1 (en) 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127
WO2019043065A1 (en) * 2017-08-29 2019-03-07 Ose Immunotherapeutics METHOD AND PREPARATION FOR SORTING T EFFECTOR LYMPHOCYTES USING ANTI-CD127 ANTIBODIES FOR CELL THERAPY APPLICATIONS
EP3790898A4 (en) * 2018-05-10 2022-03-02 Neuracle Science Co., Ltd SEQUENCE-LIKE ANTI-FAMILY ANTIBODIES 19, MEMBER A5, AND METHOD OF USE THEREOF
JP2022539753A (ja) * 2019-06-28 2022-09-13 ザ ユニバーシテイ オブ メルボルン ガンマデルタt細胞を阻害する、または活性化させる方法
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
CA3181394A1 (en) * 2020-04-27 2021-11-04 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting cd127 and use thereof
WO2021236691A1 (en) * 2020-05-18 2021-11-25 Jumaa Weinacht Hassan Composition for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
CA2655392A1 (en) 2006-05-31 2007-12-06 The Regents Of The University Of California Cd127 expression inversely correlates with foxp3 and suppressive function of cd4+ tregs
ATE542830T1 (de) 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
WO2010085643A1 (en) 2009-01-22 2010-07-29 University Of Miami Targeting il-7 signaling as a therapy for multiple sclerosis and other il-7 signaling dependent disorders
PE20121702A1 (es) 2010-01-28 2012-12-14 Glaxo Group Ltd Proteinas de enlace cd127
SA114360064B1 (ar) 2010-02-24 2016-01-05 رينات نيوروساينس كوربوريشن طرق وأجسام مضادة معارضة ضد مستقبل il-7
EP2583980A1 (en) * 2011-10-19 2013-04-24 Effimune Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates
US20150297310A1 (en) 2014-04-17 2015-10-22 Georgia Regents Research Institute, Inc. Methods for selecting a treatment for cancer
EP2955196A1 (en) * 2014-06-10 2015-12-16 Effimune Antibodies directed against CD127

Also Published As

Publication number Publication date
HRP20191445T1 (hr) 2019-11-15
MA43767A (fr) 2019-01-09
AU2017225495B2 (en) 2024-05-09
IL261330B2 (en) 2023-03-01
PL3423496T3 (pl) 2020-01-31
AU2017225495A1 (en) 2018-08-23
RS59223B1 (sr) 2019-10-31
KR20180118746A (ko) 2018-10-31
DK3423496T3 (da) 2019-08-19
EP3423496A1 (en) 2019-01-09
US20200308288A1 (en) 2020-10-01
ES2737307T3 (es) 2020-01-13
EP3423496B1 (en) 2019-07-03
US11230602B2 (en) 2022-01-25
CA3014313A1 (en) 2017-09-08
MA43767B1 (fr) 2019-08-30
IL261330A (en) 2018-10-31
IL261330B (en) 2022-11-01
LT3423496T (lt) 2019-09-25
HUE045183T2 (hu) 2019-12-30
SI3423496T1 (sl) 2019-10-30
JP7053479B2 (ja) 2022-04-12
JP2019515648A (ja) 2019-06-13
SMT201900460T1 (it) 2019-09-09
PT3423496T (pt) 2019-09-05
WO2017149394A1 (en) 2017-09-08
CY1122072T1 (el) 2020-11-25
CN109195987B (zh) 2022-05-27
CN109195987A (zh) 2019-01-11
KR102819051B1 (ko) 2025-06-12
MD3423496T2 (ro) 2020-01-31
BR112018067479A2 (pt) 2019-01-15

Similar Documents

Publication Publication Date Title
ME03446B (me) Ne-antagonistička antitela usmerena protiv alfa lanca ekstracelularnog domena il7 receptora i njihova upotreba u lečenju kancera
CN111465615B (zh) 抗cd137分子及其用途
CN113773388B (zh) 抗cd73抗体及其用途
AU2009260517B2 (en) Anti-FLT3 antibodies
CN106459203B (zh) 抗糖皮质激素诱导肿瘤坏死因子受体(gitr)的抗体及其用途
KR20240017912A (ko) 항-ccr8 항체 및 이의 용도
KR20180118725A (ko) 항-cd73 항체와의 조합 요법
CN113372434A (zh) 包含tnf家族配体三聚体的抗原结合分子
KR20170091179A (ko) Fap 및 dr5에 특이적인 이중특이성 항체, dr5에 특이적인 항체 및 사용 방법
AU2021225792B2 (en) Anti-human CD19 antibodies
KR20200006115A (ko) 항-gitr 효능제 항체에 의한 암의 치료
KR20200032185A (ko) 항 cd147 항체
AU2020316498A1 (en) Humanized anti-VEGF monoclonal antibody
KR20240017054A (ko) 항-icos 항체를 사용한 pd-l1 음성 또는 저발현 암의 치료
CN104610453A (zh) 一类抗her2双靶向抗体、其制备方法及用途
CN117999283A (zh) Tie2激动性抗体及其用途
CN101516913A (zh) Adcc活性得到增强的抗体及其制造方法
KR20240007760A (ko) 항-icos 항체의 용도
CN106565845A (zh) 抗uPAR抗原的人源化抗体H5L5及其应用
KR20210030405A (ko) Ilt4에 결합하는 항체
HK40061781A (en) Antigen binding molecules comprising a tnf family ligand trimer